Celgene hits endpoint in psoriatic arthritis but misses in rheumatoid
This article was originally published in Scrip
Celgene said on 12 July that its small-molecule phosphodiesterase 4 (PDE4) inhibitor apremilast showed statistical significance for the primary endpoint of ACR20 in the first of three pivotal Phase III clinical trials in psoriatic arthritis (PsA), but it missed the same endpoint in the first of two Phase II studies in rheumatoid arthritis (RA).
You may also be interested in...
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.